new data

guard therapeutics, rosiptor, interstitial cystitis, trial failure, new data, share price, bladder pain syndrome

Guard shares soar as new data show clinical benefit despite missing primary endpoint

Anika Sharma

Guard Therapeutics is staging a remarkable recovery following a setback in its phase 2 clinical trial for kidney injury treatment. ...